Drug Profile
Recombinant gastric lipase - Meristem
Alternative Names: Merispase®; Recombinant gastric lipaseLatest Information Update: 03 Feb 2011
Price :
$50
*
At a glance
- Originator Meristem Therapeutics
- Class Carboxylic ester hydrolases
- Mechanism of Action Lipase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pancreatic disorders
Most Recent Events
- 25 Feb 2005 Profile reviewed with information presented at the 3rd Annual BioPartnering North America (BPN-2005)
- 25 Feb 2005 Recombinant gastric lipase is available for licensing (http://www.meristem-therapeutics.com)
- 21 Jun 2004 Phase-II clinical trials in Pancreatic disorders in Europe (PO, Capsule)